Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Baseline characteristics and 5-year outcome according to baseline and 5-year anti-CCP status

From: Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis

  Anti-CCP negative at baseline Anti-CCP positive at baseline
5-year anti-CCP status Anti-CCP negative
(n= 436, 98%)
CCP-/-
Anti-CCP positive
(n= 9, 2%)
CCP-/+
P value Anti-CCP negative
(n= 9, 4.6%)
CCP+/-
Anti-CCP positive
(n= 186, 95.4%)
CCP+/+
P value
Baseline characteristic       
Age (n = 640) 51.9 (40.7, 63.1) 47.1 (42.8, 57.1) 0.39 53.4 (50.1, 58.5) 56.1 (48.1, 65.0) 0.46
Female (n = 640) 293 (67%) 7 (78%) 0.72 5 (56%) 114 (61%) 0.74
Symptom duration (n = 596) 4.9 (2.1, 10.4) 3.6 (2.5, 10.1) 0.77 4.8 (3.1, 6.1) 5.3 (2.9, 10.9) 0.82
RF +ve (n = 640) 43 (9.8%) 3 (33%) 0.06 6 (67%) 130 (70%) 1.0
Anti-CCP titer (n = 596) 0.8 (0.5, 1.4) 1.5 (1.4, 3.8) 0.0004 16.2 (13.0, 41.6) 66.8 (32, 101) 0.005
SE - 1 or 2 copies (n = 593) 213 (53%) 7 (100%) 0.017 7 (88%) 138 (78%) 1.0
HAQ (n = 639) 0.6 (0.3, 1.1) 1.1 (0.6, 1.3) 0.13 0.8 (0.4, 1.5) 0.9 (0.4, 1.6) 0.88
CRP (n = 591) 3 (0, 11) 4 (1, 14) 0.73 10 (6, 16) 11 (4, 26) 0.83
Swollen joints (n = 640) 6 (2, 12) 11 (5, 13) 0.12 5 (2, 10) 8 (4, 17) 0.22
Tender joints (n = 640) 7 (2, 16) 15 (6, 24) 0.11 7 (5, 8) 9 (4, 16) 0.24
DAS28 (n = 591) 3.7 (2.7, 4.8) 5.1 (3.2, 5.5) 0.22 4.0 (3.2, 4.5) 4.5 (3.5, 5.4) 0.30
Current smoker (n = 640) 102 (23%) 2 (22%) 1.0 0 (0) 56 (30%) 0.06
Fulfils ACR criteria (n = 640) 168 (39%) 4 (44%) 0.74 6 (67%) 135 (73%) 0.71
Outcome year 5       
Erosions (n = 523) 95 (27%) 6 (85%) 0.002 6 (75%) 125 (80%) 0.66
Larsen score (n = 521) 2 (0, 10) 35 (19, 71) 0.001 28 (5, 44) 28 (11, 43) 0.80
HAQ (n = 639) 0.6 (0, 1.4) 1.6 (0.1, 2.1) 0.24 1.1 (0.4, 1.8) 1.1 (0.5, 2) 0.40
Swollen joints (n = 475) 1 (0, 3) 2 (1, 5) 0.07 1 (0, 2) 3 (0, 8) 0.04
Tender joints (n = 475) 1 (0, 6) 3 (0, 11) 0.67 2 (0, 4) 3(0, 11) 0.20
DAS28 (n = 463) 2.2 (1.4, 3.1) 2.9 (1.6, 4.2) 0.25 1.7 (1.2, 3.4) 3.3 (2.4, 4.4) 0.03
DMARD received (n = 639) 124 (29%) 8 (89%) < 0.0001 7 (78%) 162 (87%) 0.34
Fulfils ACR criteria (n = 639) 268 (62%) 8 (89%) 0.16 8 (89%) 179 (96%) 0.32
  1. Continuous variables expressed as median (interquartile range) and compared by using the Mann-Whitney U test. Categoric variables expressed as number (percentage) and compared by using the Fisher Exact test. ACR, American College of Rheumatology criteria for rheumatoid arthritis; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug;
  2. HAQ, Health Assessment Questionnaire; RF, rheumatoid factor.